MCID: BRR002
MIFTS: 43

Barrett's Adenocarcinoma

Categories: Cancer diseases

Aliases & Classifications for Barrett's Adenocarcinoma

MalaCards integrated aliases for Barrett's Adenocarcinoma:

Name: Barrett's Adenocarcinoma 12 14 69
Adenocarcinoma Arising in Barrett's Mucosa 12
Barrett Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:7941
NCIt 46 C7027
UMLS 69 C1332460

Summaries for Barrett's Adenocarcinoma

MalaCards based summary : Barrett's Adenocarcinoma, also known as adenocarcinoma arising in barrett's mucosa, is related to adenocarcinoma and protoplasmic astrocytoma. An important gene associated with Barrett's Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Endometrial cancer and Gastric cancer. The drugs Epinephrine and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include lymph node, endothelial and heart, and related phenotypes are behavior/neurological and cellular

Related Diseases for Barrett's Adenocarcinoma

Diseases related to Barrett's Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 116)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 29.7 CDKN2A ERBB2 KRAS PTGS2 TP53
2 protoplasmic astrocytoma 10.5 PTGS2 TP53
3 uterine corpus serous adenocarcinoma 10.5 ERBB2 TP53
4 glioma susceptibility 1 10.5 ERBB2 TP53
5 brain stem astrocytic neoplasm 10.5 CDKN2A TP53
6 non-proliferative fibrocystic change of the breast 10.5 ERBB2 TP53
7 squamous cell carcinoma of the oropharynx 10.5 CDKN2A TP53
8 fallopian tube adenocarcinoma 10.5 ERBB2 TP53
9 spitz nevus 10.5 CDKN2A TP53
10 breast papillomatosis 10.5 CDKN2A ERBB2
11 keratinizing squamous cell carcinoma 10.5 CDKN2A TP53
12 uterine body mixed cancer 10.5 ERBB2 TP53
13 squamous cell carcinoma of the larynx 10.5 CDKN2A TP53
14 fallopian tube endometrioid adenocarcinoma 10.5 CDKN2A ERBB2
15 bartholin's gland benign neoplasm 10.5 CDKN2A TP53
16 bowenoid papulosis 10.5 CDKN2A PTGS2
17 pleomorphic adenoma carcinoma 10.4 ERBB2 TP53
18 bladder carcinoma in situ 10.4 CDKN2A TP53
19 anal squamous cell carcinoma 10.4 CDKN2A TP53
20 thyroid lymphoma 10.4 CDKN2A TP53
21 vulva squamous cell carcinoma 10.4 CDKN2A TP53
22 vulval paget's disease 10.4 CDKN2A ERBB2
23 bone squamous cell carcinoma 10.4 CDKN2A TP53
24 microglandular adenosis 10.4 ERBB2 TP53
25 scrotal carcinoma 10.4 CDKN2A TP53
26 vulva adenocarcinoma 10.4 CDKN2A ERBB2
27 glycogen-rich clear cell breast carcinoma 10.4 CDKN2A TP53
28 anogenital venereal wart 10.4 CDKN2A TP53
29 hyperplastic polyposis syndrome 10.4 KRAS TP53
30 mutyh-associated polyposis 10.4 KRAS TP53
31 small cell neuroendocrine carcinoma 10.4 CDKN2A TP53
32 breast benign neoplasm 10.4 ERBB2 TP53
33 papilledema 10.4 OGG1 TP53
34 thoracic benign neoplasm 10.4 ERBB2 TP53
35 meningeal melanomatosis 10.4 CDKN2A TP53
36 tumor suppressor gene on chromosome 11 10.4 ERBB2 KRAS
37 cervical adenosquamous carcinoma 10.4 CDKN2A PTGS2
38 dedifferentiated liposarcoma 10.3 CDKN2A TP53
39 uterine corpus cancer 10.3 ERBB2 TP53
40 uterine carcinosarcoma 10.3 ERBB2 PTGS2 TP53
41 mature teratoma 10.3 KRAS TP53
42 ductal carcinoma in situ 10.3 ERBB2 PTGS2 TP53
43 balanitis xerotica obliterans 10.3 CDKN2A PTGS2 TP53
44 transitional cell carcinoma 10.3 ERBB2 PTGS2 TP53
45 bladder squamous cell carcinoma 10.3 CDKN2A PTGS2 TP53
46 oral leukoplakia 10.3 CDKN2A ERBB2 TP53
47 actinic keratosis 10.3 CDKN2A PTGS2 TP53
48 pulmonary blastoma 10.3 KRAS TP53
49 skin melanoma 10.3 CDKN2A PTGS2 TP53
50 pre-malignant neoplasm 10.3 CDKN2A ERBB2 TP53

Graphical network of the top 20 diseases related to Barrett's Adenocarcinoma:



Diseases related to Barrett's Adenocarcinoma

Symptoms & Phenotypes for Barrett's Adenocarcinoma

MGI Mouse Phenotypes related to Barrett's Adenocarcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.03 TP53 ADIPOR1 KRAS ADIPOR2 OGG1 CDKN2A
2 cellular MP:0005384 10.01 ERBB2 ADIPOR1 KRAS OGG1 CDKN2A PTGS2
3 homeostasis/metabolism MP:0005376 9.97 FHIT ADIPOR1 KRAS ADIPOR2 OGG1 CDKN2A
4 digestive/alimentary MP:0005381 9.85 TP53 FHIT KRAS CDKN2A PTGS2 ERBB2
5 liver/biliary system MP:0005370 9.8 ADIPOR1 KRAS ADIPOR2 OGG1 CDKN2A PTGS2
6 muscle MP:0005369 9.63 TP53 ADIPOR1 KRAS CDKN2A PTGS2 ERBB2
7 neoplasm MP:0002006 9.5 FHIT KRAS OGG1 CDKN2A PTGS2 ERBB2
8 skeleton MP:0005390 9.17 TP53 ADIPOR1 KRAS ADIPOR2 CDKN2A PTGS2

Drugs & Therapeutics for Barrett's Adenocarcinoma

Drugs for Barrett's Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 10)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epinephrine Approved, Vet_approved 51-43-4 5816
2 Racepinephrine Approved 329-65-7
3
Vitamin A Approved, Nutraceutical, Vet_approved 68-26-8, 11103-57-4 445354
4
acetic acid Approved, Nutraceutical 64-19-7 176
5
Retinol acetate 127-47-9 10245972
6 Retinol palmitate
7 Adjuvants, Immunologic
8 Protective Agents
9 Epinephryl borate
10 retinol Nutraceutical

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Aceto-whitening in the Assessment of Gastrointestinal Neoplasia Unknown status NCT01618643
2 ESD Versus EMR for Treatment of Early Barrett`s Adenocarcinoma Completed NCT01871636
3 Neoplastic Barrett Esophagus: Endoscopic Piecemeal vs. En Bloc Resection Recruiting NCT03427346
4 Endoscopic Mucosal Resection and Cellular Matrix Enrolling by invitation NCT03240679

Search NIH Clinical Center for Barrett's Adenocarcinoma

Genetic Tests for Barrett's Adenocarcinoma

Anatomical Context for Barrett's Adenocarcinoma

MalaCards organs/tissues related to Barrett's Adenocarcinoma:

38
Lymph Node, Endothelial, Heart, Bone

Publications for Barrett's Adenocarcinoma

Articles related to Barrett's Adenocarcinoma:

(show top 50) (show all 102)
# Title Authors Year
1
Treatment of long-segment Barrett's adenocarcinoma by complete circular endoscopic submucosal dissection: a case report. ( 29351773 )
2018
2
Genome-Wide Analysis of Barrett's Adenocarcinoma. A First Step Towards Identifying Patients at Risk and Developing Therapeutic Paths. ( 29223109 )
2018
3
Impact of RAD51C-mediated Homologous Recombination on Genomic Integrity in Barrett's Adenocarcinoma Cells. ( 29399538 )
2017
4
Tumor location is a risk factor for lymph node metastasis in superficial Barrett's adenocarcinoma. ( 28924592 )
2017
5
A case of simultaneous esophageal squamous cell carcinoma and Barrett's adenocarcinoma. ( 27220657 )
2016
6
A case of Barrett's adenocarcinoma with marked endoscopic morphological changes in Barrett's esophagus over a long follow-up period of 15a88years. ( 26946036 )
2016
7
Proton Pump Inhibitors Display Antitumor Effects in Barrett's Adenocarcinoma Cells. ( 27932981 )
2016
8
Single center experience of endoscopic submucosal dissection (ESD) in early Barrett's adenocarcinoma. ( 25294533 )
2015
9
STAT3 expression, activity and functional consequences of STAT3 inhibition in esophageal squamous cell carcinomas and Barrett's adenocarcinomas. ( 23912451 )
2014
10
Clinical outcomes of endoscopic submucosal dissection for superficial Barrett's adenocarcinoma. ( 24565073 )
2014
11
Ischemic heart disease, factor predisposing to Barrett's adenocarcinoma: A case control study. ( 25133047 )
2014
12
Volumetric laser endomicroscopy detects subsquamous Barrett's adenocarcinoma. ( 24496431 )
2014
13
The evil lies below the surface: Subsquamous tumor extension in Barrett's adenocarcinoma. ( 26134612 )
2014
14
Barrett's adenocarcinoma in long-segment Barrett's esophagus successfully detected by narrow-band imaging with magnifying endoscopy. ( 23617678 )
2013
15
Reduced expression of I+GlcNAc in Barrett's oesophagus adjacent to Barrett's adenocarcinoma - a possible biomarker to predict the malignant potential of Barrett's oesophagus. ( 24117499 )
2013
16
Small Barrett's adenocarcinoma, 3 mm in size, in long-segment Barrett's esophagus detected after 4 years of follow up. ( 23617677 )
2013
17
Current status of endoscopic diagnosis and treatment of superficial Barrett's adenocarcinoma in Asia-Pacific region. ( 23617667 )
2013
18
Differences in the Characteristics of Barrett's Esophagus and Barrett's Adenocarcinoma between the United States and Japan. ( 23606979 )
2013
19
Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth. ( 23604115 )
2013
20
A second-generation 2-Methoxyestradiol prodrug is effective against Barrett's adenocarcinoma in a mouse xenograft model. ( 23288782 )
2013
21
Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma. ( 23180947 )
2012
22
Targeting PI3K and RAD51 in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth. ( 22399496 )
2012
23
MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett's adenocarcinoma. ( 22365974 )
2012
24
Increased expression of the 5-lipoxygenase pathway and its cellular localization in Barrett's adenocarcinoma. ( 22690932 )
2012
25
A rare case of Barrett's adenocarcinoma including squamous cell carcinoma component. ( 26190613 )
2011
26
Barrett's adenocarcinoma of the esophagus: better outcomes through new methods of diagnosis and treatment. ( 21629515 )
2011
27
How much length of the distal esophagus is removed by transhiatal approach for squamous cell carcinoma and Barrett's adenocarcinoma in Japanese patients? ( 22234066 )
2011
28
Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome. ( 21423218 )
2011
29
Human Barrett's adenocarcinoma of the esophagus, associated myofibroblasts, and endothelium can arise from bone marrow-derived cells after allogeneic stem cell transplant. ( 20677919 )
2011
30
A case of early Barrett's adenocarcinoma repeatedly developing multiple metachronous lesions shortly after endoscopic therapy: an analysis for genetic and epigenetic alterations. ( 20650453 )
2010
31
Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. ( 20840671 )
2010
32
Barrett's adenocarcinoma 52 years after subtotal esophagectomy for pediatric peptic stricture. ( 20103354 )
2010
33
Differences in the definitions used for esophageal and gastric diseases in different countries: endoscopic definition of the esophagogastric junction, the precursor of Barrett's adenocarcinoma, the definition of Barrett's esophagus, and histologic criteria for mucosal adenocarcinoma or high-grade dysplasia. ( 19828957 )
2009
34
Genome-wide analysis of genetic alterations in Barrett's adenocarcinoma using single nucleotide polymorphism arrays. ( 18663352 )
2009
35
Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort. ( 19620873 )
2009
36
DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma. ( 18664505 )
2009
37
Comparison of DNA histograms by standard flow cytometry and image cytometry on sections in Barrett's adenocarcinoma. ( 18513411 )
2008
38
No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett's adenocarcinoma relationship case-control study. ( 18349297 )
2008
39
Results of a multimodal therapy in patients with stage IV Barrett's adenocarcinoma. ( 18802733 )
2008
40
Immunohistochemical expression of p63 in esophageal Barrett's adenocarcinoma. ( 21479434 )
2008
41
Corn-derived carbohydrate inositol hexaphosphate inhibits Barrett's adenocarcinoma growth by pro-apoptotic mechanisms. ( 18202808 )
2008
42
Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. ( 18676772 )
2008
43
Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma. ( 17376806 )
2007
44
Usefulness of magnifying endoscopy with narrow band imaging for the detection of specialized intestinal metaplasia in columnar-lined esophagus and Barrett's adenocarcinoma. ( 17185078 )
2007
45
Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas. ( 17227303 )
2007
46
Transcriptional oncogenomic hot spots in Barrett's adenocarcinomas: serial analysis of gene expression. ( 17636545 )
2007
47
Familial trends of inheritance in gastro esophageal reflux disease, Barrett's esophagus and Barrett's adenocarcinoma: 20 families. ( 17227311 )
2007
48
Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis. ( 16921482 )
2006
49
Angiogenic switch in Barrett's adenocarcinoma: the role of vascular endothelial growth factor. ( 16720317 )
2006
50
NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin. ( 17244951 )
2006

Variations for Barrett's Adenocarcinoma

Copy number variations for Barrett's Adenocarcinoma from CNVD:

7 (show top 50) (show all 60)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 39411 10 114900000 119100000 Gain ABLIM1 Barrett''s adenocarcinoma
2 39412 10 114900000 119100000 Gain AFAP1L2 Barrett''s adenocarcinoma
3 42467 10 34500000 38800000 Gain CCNY Barrett''s adenocarcinoma
4 42468 10 34500000 38800000 Gain CUL2 Barrett''s adenocarcinoma
5 65755 12 21200000 26300000 Gain SSPN Barrett''s adenocarcinoma
6 66184 12 26300000 27700000 Gain ARNTL2 Barrett''s adenocarcinoma
7 66185 12 26300000 27700000 Gain TM7SF3 Barrett''s adenocarcinoma
8 73111 12 91200000 94800000 Gain KRT19P2 Barrett''s adenocarcinoma
9 74577 13 109100000 114142980 Gain Barrett''s adenocarcinoma
10 75797 13 24400000 26700000 Gain Barrett''s adenocarcinoma
11 79796 13 77800000 86500000 Gain SOX1 Barrett''s adenocarcinoma
12 81034 14 100400000 102200000 Gain SLC25A29 Barrett''s adenocarcinoma
13 88798 14 95400000 100400000 Gain TCL1A Barrett''s adenocarcinoma
14 88799 14 95400000 100400000 Gain TCL1B Barrett''s adenocarcinoma
15 107009 17 11200000 15900000 Loss RICH2 Barrett''s adenocarcinoma
16 114436 17 47600000 54900000 Gain CUEDC1 Barrett''s adenocarcinoma
17 115246 17 55600000 58400000 Gain LRRC37A3 Barrett''s adenocarcinoma
18 116543 17 6800000 11200000 Loss MYH13 Barrett''s adenocarcinoma
19 116544 17 6800000 11200000 Loss TP53 Barrett''s adenocarcinoma
20 122243 18 54400000 57100000 Loss Barrett''s adenocarcinoma
21 125938 19 16100000 19800000 Gain AP1M1 Barrett''s adenocarcinoma
22 127254 19 30200000 37100000 Gain ZNF536 Barrett''s adenocarcinoma
23 134771 2 106700000 108600000 Gain GCC2 Barrett''s adenocarcinoma
24 141056 2 205600000 209100000 Gain Barrett''s adenocarcinoma
25 144816 2 29800000 31900000 Gain ALK Barrett''s adenocarcinoma
26 151523 20 22300000 25700000 Gain SSTR4 Barrett''s adenocarcinoma
27 151524 20 22300000 25700000 Loss CST4 Barrett''s adenocarcinoma
28 152533 20 31500000 33900000 Gain CEP250 Barrett''s adenocarcinoma
29 154854 20 49200000 54400000 Gain CBLN4 Barrett''s adenocarcinoma
30 170891 3 161200000 169200000 Gain BCHE Barrett''s adenocarcinoma
31 172565 3 184200000 186000000 Gain MAGEF1 Barrett''s adenocarcinoma
32 172566 3 184200000 186000000 Gain MUC13 Barrett''s adenocarcinoma
33 172567 3 184200000 186000000 Gain VPS8 Barrett''s adenocarcinoma
34 177566 3 58500000 63700000 Loss Barrett''s adenocarcinoma
35 196847 5 172200000 176500000 Gain MSX2 Barrett''s adenocarcinoma
36 203652 6 1 2300000 Gain Barrett''s adenocarcinoma
37 204555 6 11200000 13500000 Gain PHACTR1 Barrett''s adenocarcinoma
38 205460 6 127300000 130400000 Gain C6orf190 Barrett''s adenocarcinoma
39 205461 6 127300000 130400000 Gain PTPRK Barrett''s adenocarcinoma
40 212308 6 36800000 40600000 Gain DNAH8 Barrett''s adenocarcinoma
41 219021 7 120900000 123600000 Loss SLC13A1 Barrett''s adenocarcinoma
42 219022 7 120900000 123600000 Loss TAS2R16 Barrett''s adenocarcinoma
43 225150 7 43300000 46600000 Gain RAMP3 Barrett''s adenocarcinoma
44 225833 7 50900000 53900000 Gain Barrett''s adenocarcinoma
45 227260 7 66100000 71800000 Gain CALN1 Barrett''s adenocarcinoma
46 227261 7 66100000 71800000 Gain WBSCR17 Barrett''s adenocarcinoma
47 227796 7 7200000 13300000 Gain ICA1 Barrett''s adenocarcinoma
48 231014 8 101600000 106100000 Gain ANKRD46 Barrett''s adenocarcinoma
49 231021 8 101600000 106100000 Gain RNF19 Barrett''s adenocarcinoma
50 232059 8 110600000 112200000 Gain PKHD1L1 Barrett''s adenocarcinoma

Expression for Barrett's Adenocarcinoma

Search GEO for disease gene expression data for Barrett's Adenocarcinoma.

Pathways for Barrett's Adenocarcinoma

Pathways related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 22)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.82 CDKN2A ERBB2 FHIT KRAS TP53
2
Show member pathways
12.5 CDKN2A ERBB2 GSTT2 KRAS TP53
3
Show member pathways
12.49 ERBB2 KRAS PTGS2 TP53
4
Show member pathways
12.34 ERBB2 KRAS RAD51 TP53
5
Show member pathways
12.32 CDKN2A ERBB2 KRAS TP53
6 12.2 CDKN2A ERBB2 KRAS PTGS2 TP53
7 11.99 KRAS PTGS2 TP53
8 11.97 CDKN2A KRAS TP53
9 11.95 KRAS RAD51 TP53
10 11.89 CDKN2A ERBB2 GSTT2 KRAS PTGS2 RAD51
11
Show member pathways
11.88 ADIPOR1 ADIPOR2 KRAS TP53
12 11.84 CDKN2A KRAS TP53
13 11.75 CDKN2A KRAS TP53
14 11.73 CDKN2A ERBB2 KRAS TP53
15 11.62 FHIT PTGS2 TP53
16
Show member pathways
11.54 CDKN2A ERBB2 KRAS RAD51 TP53
17 11.45 ERBB2 KRAS TP53
18 11.42 CDKN2A ERBB2 KRAS TP53
19 11.32 CDKN2A ERBB2 GSTT2 TP53
20 11.07 RAD51 TP53
21 10.92 CDKN2A TP53
22
Show member pathways
10.91 CDKN2A TP53

GO Terms for Barrett's Adenocarcinoma

Cellular components related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.17 CDKN2A COX7A2 FHIT KRAS OGG1 RAD51

Biological processes related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.78 CDKN2A ERBB2 KRAS TP53
2 aging GO:0007568 9.72 OGG1 PTGS2 TP53
3 fatty acid metabolic process GO:0006631 9.7 ADIPOR1 ADIPOR2 PTGS2
4 response to oxidative stress GO:0006979 9.69 OGG1 PTGS2 TP53
5 response to organic cyclic compound GO:0014070 9.67 PTGS2 RAD51 TP53
6 response to drug GO:0042493 9.67 OGG1 PTGS2 RAD51 TP53
7 cellular response to gamma radiation GO:0071480 9.56 RAD51 TP53
8 response to X-ray GO:0010165 9.54 RAD51 TP53
9 fatty acid oxidation GO:0019395 9.46 ADIPOR1 ADIPOR2
10 positive regulation of cellular senescence GO:2000774 9.43 CDKN2A KRAS
11 Ras protein signal transduction GO:0007265 9.43 CDKN2A KRAS TP53
12 replicative senescence GO:0090399 9.4 CDKN2A TP53
13 regulation of fatty acid biosynthetic process GO:0042304 9.32 ADIPOR1 ADIPOR2
14 adiponectin-activated signaling pathway GO:0033211 9.16 ADIPOR1 ADIPOR2
15 negative regulation of immature T cell proliferation in thymus GO:0033088 8.96 CDKN2A ERBB2
16 negative regulation of cell growth GO:0030308 8.92 ADIPOR1 ADIPOR2 CDKN2A TP53

Molecular functions related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.63 ADIPOR1 ADIPOR2 ERBB2 FHIT RAD51 TP53
2 nucleotide binding GO:0000166 9.56 ERBB2 FHIT KRAS RAD51
3 adiponectin binding GO:0055100 8.96 ADIPOR1 ADIPOR2
4 adipokinetic hormone receptor activity GO:0097003 8.62 ADIPOR1 ADIPOR2

Sources for Barrett's Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....